Advances in genetic analysis and a greater understanding of human immunodeficiency virus (HIV
Introduction
The limitations of combination antiviral drug therapies for human immunodeficiency virus (HIV-1) have lead to the design and development of alternative approaches to therapeutic intervention. 1 Indeed, the high mutation rate of HIV generates new variants of the virus which are resistant to conventional therapies. In addition to viral resistance, current treatments for HIV infection are hindered by their cost, availability, patient noncompliance and toxicity. 2 As accessible and affordable alternatives, strategies involving gene therapy have been proposed to restore immune function in infected patients using a variety of effector molecules to inhibit HIV replication in CD4 + cells, reduce the cytopathic effects of viral infection and/or induce death of infected cells. 3 Exploration of mechanisms for regulation of HIV replication have led to the design and evaluation of a large number of genetic antiviral strategies including the expression of dominant/negative mutant proteins, RNA decoys, intracellular antibodies and gene interference therapies. 1 The most common approaches to gene interference for the treatment of HIV infection have mainly involved antisense technologies or ribozymes. 3 However, therapeutic approaches based on these technologies have encountered limitations. 4, 5 are thought to be mediated by RNase H which cleaves the target mRNA strand of an RNA-DNA hybrid. 6, 7 Cleavage at non-targeted sites is a problem associated with antisense technologies as RNase H does not require a 100% complementary duplex to degrade hybridized mRNA. [8] [9] [10] Furthermore, antisense molecules act in a 1:1 stoichiometric relationship with target mRNA and possess no inherent 'catalytic turnover', thereby requiring continuous administration of these molecules to elicit a sustained therapeutic effect in treated cells. 5 'Hairpin' or 'hammerhead' ribozymes may be able to overcome the deficiencies encountered with antisense technologies, as these RNA enzymes possess autocatalytic activity that permits the repeated recognition and cleavage of multiple target mRNA transcripts within an infected cell. 11 As with antisense technologies, these catalytic RNA molecules can be designed to specifically recognize target mRNA sequences from foreign or aberrant genes, but are limited by the requirement for the presence of specific nucleotide sequences (-GUX-) in the target mRNA for cleavage to occur. 12 Furthermore, a single point mutation in the required GUX sequence could render ribozymes ineffective for target mRNA cleavage. 5 With technological advances in genetic analysis and a greater understanding of HIV molecular pathogenesis that have permitted the identification of specific gene targets, it is imperative to develop gene interference strategies that combine the attributes of antisense and ribozyme technologies and overcome their limitations.
One promising gene interference technology has been investigated and characterized for over 20 years following its discovery by Sidney Altman in the late 1970s. 13 RNase P, a ribonucleoprotein that consists of enzyme and RNA subunits, catalyzes the hydrolysis reaction that removes the 5' leader sequence from tRNA precursors to form mature tRNA molecules. 14, 15 This essential enzymatic activity has been found in all cell types, including prokaryotes and eukaryotes. 16 A general strategy for gene targeting has been developed based upon the fact that the 3' proximal sequence of the RNA component of RNase P, called the external guide sequence (EGS), can be modified to hybridize with complementary target mRNA. 4, 17, 18 The EGS is designed to leave a 5'-ACCAC-3' unpaired stretch required for cleavage by the RNase P protein component following hybridization. In principle, any mRNA of known sequence can be targeted for precise cleavage by RNase P through use of custom-designed EGS RNA without the restriction of a specific nucleotide sequence in the target mRNA. 18, 19 Subsequent studies of substrate recognition and RNase P cleavage requirements have provided insight into structural modifications of the RNA component of RNase P that may be implemented to enhance target mRNA cleavage. 20 As such, RNase P molecules combine the attributes of antisense technologies, as well as ribozymes and transcend several of their limitations.
We have designed a truncated EGS that specifically recognizes and hybridizes to the U5 region of the 5' leader sequence of HIV-1 ( Figure 1a ). This region is highly conserved across HIV-1 clades and is present on all forms of HIV RNA including incoming RNA strands and mRNA transcripts expressed following infection. [21] [22] [23] [24] Successful cleavage at this region of the viral RNA results in degradation of the genome due to removal of the pro- tective 5'cap. A disabled EGS devoid of the T-stem and loop required for RNase P enzyme recognition and cleavage was constructed to control for antisense inhibition (Figure 1b) . For our experiments, the EGS is complementary to 10 base pairs from the HIV-1 U5 region. This length of EGS should be suitable for target specificity without creating aberrant secondary structure that may interfere with target mRNA hybridization or RNase Pmediated cleavage. The genes encoding for the active and disabled U5 EGS was cloned into Moloney-based retroviral vectors for delivery to target cells. The following investigation describes the potent inhibition of HIV-1 replication and viral pathogenesis in CD4 + T cells expressing this novel RNase P molecule.
Figure 1 Diagrams of the truncated U5 EGS (560) and (560D). (a) The active form of the U5 EGS (560) including the T-stem and loop, as well as the EGS of the acceptor stem that is complementary to the U5 region of HIV-1 mRNA. (b) The disabled form U5 EGS (560D

Results
Retroviral gene expression
The CD4
+ T cell line, M4C8, was transfected with retroviral expression plasmids containing single copies of the genes for either the U5 EGS (560) or the disabled U5 EGS (560D) driven by the tRNA VAL promoter. The disabled U5 EGS (560D) lacked the T-stem loop required for recognition and cleavage of target mRNA by the RNase P enzyme, but shared the identical EGS with the active U5 EGS (560) to control for antisense effect. Following selection of transfected cells for neomycin resistance, untreated M4C8 cells and cells expressing either the active or disabled U5 EGS molecule were evaluated for the presence and expression of the neomycin resistance (Neo R ) gene, as well as each U5 EGS (560 and 560D) using real-time PCR (Table 1) . These assays were used to confirm transfection of the retroviral plasmids, as well as expression of the genes carried by these constructs and eliminate target cell clones that generated spontaneous resistance to G418. Theoretically, Northern blot analysis could be used to detect EGS expression from the tRNA promoter. However, the size of the EGS (>35 base pairs) makes detection difficult and quantitation impractical. All cells were removed from G418 selection 7 days before RNA isolation as subsequent HIV infection and analysis would be completed on cells no longer cultured in the presence of G418. cDNA was generated from isolated RNA samples and evaluated for Neo R and U5 EGS (560 and 560D) expression, as well as expression of a common 'housekeeping' gene, Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using real-time RT-PCR. The crossing points, defined as the cycle where fluorescent signal from amplified products enters the linear phase, were used in a ratio as a comparative measure of Neo R expression standardized by the level of GAPDH for each experimental and untreated cell population. Expression of the Neo R gene was confirmed for all cultures of experimental and untreated M4C8 cells and there was no significant difference in levels of gene expression (Table 1) . Furthermore, the Neo R mRNA transcript could be detected in these cell populations at greater than 60 days after selection and removal of G418. Expression of each RNase P EGS was confirmed for each corresponding M4C8 population following selection using real-time PCR. Each of the U5 EGS were expressed at similar levels when compared with levels of the 'housekeeping' control gene, GAPDH (Table 1) . Thus, expression of the Neo mids was confirmed for M4C8 cells transfected with either the disabled or active U5 EGS used for this investigation.
Target cell proliferation following treatment
Experimental (active or disabled U5 EGS) and untreated M4C8 cells were subsequently evaluated for cell proliferation using a commercial colorimetric assay based upon the conversion of tetrazolium salts to formazan dye by viable, metabolically active cells. Cells were removed from G418-supplemented media for a period of 7 days before evaluated of cell viability and proliferation. Experimental and control cells were seeded in quadruplicate at 10 3 or 10 4 cells per well in a 96-well plate and evaluated for formazan dye conversion after 5 days ( Figure 2 ). Levels of cell proliferation for non-transfected and M4C8 cells expressing the U5 EGS (560) were not significantly different from one another. M4C8 cells expressing the disabled U5 EGS (560D) were slightly more active than cells expressing the U5 EGS (560) or untreated controls. This small difference in cell growth is consistent for each M4C8 culture expressing the inactive U5 EGS (560D) and is not attributed to transfection or components of the retroviral plasmid. Nevertheless, all M4C8 cells utilized for this investigation had similar levels of viability, metabolism and proliferation indicating Gene Therapy no detectable toxicity associated with the active or disabled U5 EGS molecules.
Inhibition of HIV-1 production
Triplicate cultures of experimental and untreated M4C8 cells were exposed to HIV-1 MN and evaluated for p24 gag antigen production, HIV-1 proviral DNA, levels of CD4 expression and the percentage of apoptotic cells over time. Cell and supernatant samples were harvested in triplicate from each culture at regular intervals for a period of 32 days. As an indication of productive HIV infection, levels of p24 antigen were detectable in the supernatants of untreated M4C8 and experimental cells expressing the disabled U5 EGS (560D) molecule at 7 days after infection ( Figure 3a ). The level of p24 antigen in the supernatant of these cultures continued to increase until reaching the maximum threshold of the assay between 10 to 14 days after infection. Levels of p24 antigen remained elevated in these control cultures to 32 days. In complete contrast, no p24 antigen could be detected in the supernatants from cultures of M4C8 cells expressing the active U5 EGS (560) and exposed to HIV-1 MN over the same period of time. Furthermore, untreated M4C8 and experimental M4C8 expressing either the active or disabled U5 EGS were permissive to HIV-2 KR infection as indicated by elevated p26 antigen levels in culture supernatants and the rapid formation of syncytia in infected cultures (Figure 3b ). This observation would indicate that the selected cells are permissive to HIV-2 infection but the active U5 EGS (560) specifically inhibits HIV-1 infection and replication. Collectively, these data suggest that M4C8 cells expressing the active U5 EGS (560) were either resistant to HIV-1 infection due to cleavage of incoming virus or did not produce HIV-1 particles as viral mRNA is cleaved following transcription.
Inhibition of proviral DNA integration
Genomic DNA was isolated from cell samples and evaluated for the presence of HIV-1 proviral DNA using PCR (data not shown). A DNA fragment corresponding to the conserved region of the HIV-1 gag protein was readily amplified in untreated M4C8 and M4C8 expressing the disabled U5 EGS (560D). However, no proviral DNA could be amplified from genomic DNA isolated from M4C8 expressing the active U5 EGS (560) throughout the 32 day period after exposure to HIV-1. These results corresponded with the contrasting levels of p24 antigen measured for each culture supernatant and indicated that the active U5 EGS (560) may interfere with the HIV cycle 
cells for each cell population were incubated with either HIV-1 MN or HIV-2 KR at an MOI of 0.01. Supernatants were evaluated for levels of gag antigen as a measure of HIV infection and viral production. (a) Levels of HIV-1 MN p24 gag antigen. ᮀ, M4C8 #1; , M4C8 #2; ̅, M4C8 + U5 EGS (560)#1;̆, M4C8 + U5 EGS (560)#2; ᭺, M4C8 + U5 EGS (560D)#1; ¼, M4C8 + U5 EGS (560D)#2. (b) Levels of HIV-2 KR p26 gag antigen. HIV-2 KR has a rapid pathogenesis in M4C8 cells. By 14 days after infection with HIV-2 KR, most cells in infected cultures were dead. ᮀ, M4C8 #1 non-infected; , M4C8 #1;̆, M4C8 + U5 EGS (560)#1; ¼, M4C8 + U5 EGS (560D)#1.
before integration of proviral DNA into the host cell genome.
Active U5 EGS (560) preserves CD4 expression
The levels of p24 antigen in the culture supernatant also correlated well with the loss of CD4 from the surface of untreated M4C8 and cells expressing the disabled U5 EGS (560D) (Figure 4) . Before exposure to HIV-1 MN, greater than 95% of all cells, including experimental and control cultures, were observed to express CD4 on their surface as detected by flow cytometry. By 11 days after infection, there was little or no decrease in CD4 levels for untreated M4C8 cells or those expressing the active U5 EGS (560). However, only 55-60% of the M4C8 treated with the disabled U5 EGS (560D) expressed CD4 on their surface. At 21 days after infection, both the untreated 
Inhibition of apoptosis by active U5 EGS (560)
Cell cultures were also evaluated for the number of cells undergoing apoptosis using Annexin V stain and flow cytometry over a period of 30 days ( Figure 5 ). Before infection with HIV-1 MN, cultures of non-transfected, experimental and control M4C8 had low levels of cells undergoing apoptosis (2.66-5.12%). At 7 days after infec- tion with HIV-1, the percentage of cells undergoing or completing apoptosis was elevated in untreated M4C8 cells (17%) and more so in M4C8 cells expressing the disabled U5 EGS (560D) (27.63%). However, the percentage of apoptotic cells remained low (5.12%) for M4C8 treated with the active U5 EGS (560). At 11 and 14 days after infection with HIV-1 MN, levels of apoptotic cells were elevated in untreated M4C8 (7.63-12.9%) and cells expressing the disabled U5 EGS (560D) (23-29.22% ). Over the same time period, the levels of apoptotic cells exposed to HIV-1 MN and expressing the active U5 EGS (560) remained similar to background levels for uninfected control cultures (2.3-4.8%). Cell samples harvested after day 14 indicated the generation of CD4 Ϫ , HIV-1-producing M4C8 clones in untreated M4C8 cells and cells treated with the disabled U5 EGS (560) that were resistant to virus-mediated death.
These observations were corroborated with light microscopic evaluation of the control and HIV infected cultures ( Figure 6 ). M4C8 expressing the disabled U5 EGS (560D) and exposed to HIV-1 MN developed large and numerous syncytia by day 7. Syncytia remained present to day 14 after which viable HIV-infected, CD4 Ϫ clones began to develop. Similar, but less numerous, syncytia were observed in untreated M4C8 cultures infected with HIV-1 at 7 days after infection. Once again these giant multi-nucleated cells were observed to day 14 when CD4 Ϫ , HIV-infected isolates gained prominence. Conversely, cultures of M4C8 cells expressing the active U5 EGS (560) as well as non-infected controls for each cell type, remained free of syncytia formation and CD4
+ to 30 days after infection. These observations suggest that 
MN at 14 days after infection; (c) M4C8 expressing the active U5 EGS (560) and exposed to HIV-1 MN at 30 days after infection; (d) M4C8 expressing the disabled U5 EGS (560D) and exposed to HIV-1 MN at 14 days after infection. Arrows indicate large cell syncytia formed by the fusion of HIV-1-infected cells with adjacent CD4
+ cells.
Gene Therapy
CD4
+ cells expressing the active U5 EGS (560) have a survival advantage over untreated M4C8 or cells expressing a disabled U5 RNase P EGS following exposure to HIV-1 MN.
Discussion
The RNase P complex may offer an excellent alternative to conventional gene interference therapies for the treatment of infectious diseases and human malignancies. The RNA component contains the external guide sequence (EGS) which can be designed to recognize and hybridize to almost any target mRNA. The enzyme component of RNase P required for cleavage of the RNA hybrid is ubiquitously expressed in all cells that express tRNA and translate proteins. The result is an effective and versatile gene interference system that is independent of the target mRNA sequence and can be applied in every cell type.
In this investigation, we designed a truncated RNase P EGS that targeted the highly conserved U5 region of the HIV-1 genome present in incoming viral genomes, as well as viral mRNA transcripts produced following infection. A CD4 + T cell line expressing the U5 EGS (560) was protected from HIV-1 infection with no loss of CD4 expression, no detectable integrated proviral DNA, no measurable viral replication and no observable cytopathology. In contrast, untreated M4C8 cells and cells expressing a disabled U5 EGS (560D) antisense control molecule were permissive to infection with HIV-1 MN and presented with the key characteristics of HIV cytopathology. These data indicate that inhibition of HIV-1 infection or replication was not due to an antisense effect as cells expressing the disabled U5 EGS (560D), with the identical hybridization region but lacking the T-stem for enzyme recognition, elicited no such results. Furthermore, this inhibition of viral infection observed with CD4 + T cells treated with the active U5 EGS (560) was specific for HIV-1, as these experimental cells as well as controls were readily infected with HIV-2. Since the target sequence for U5 EGS (560) is not present in HIV-2, this specificity is not surprising. However, this observation further suggests that the inhibition observed in cells expressing the active RNase P EGS is not due to the cells being rendered non-permissive to HIV, but rather specifically protected from HIV-1 strains with genomes containing the target sequence. Theoretically, the inhibition of HIV-1 infection and/or replication should extend to most strains of HIV-1 as the target sequence is highly conserved across viral clades.
The point in the viral replication cycle where RNase Pmediated inhibition of HIV-1 infection occurs is unclear. One possible scenario would suggest that the U5 EGS (560) could inhibit viral infection following viral entry into the cytoplasm and before generation of proviral DNA. In the current investigation, the retroviral plasmids transfected into the M4C8 cells could potentially produce two different transcripts of the U5 EGS. One would be fused with the neomycin resistance (Neo R ) mRNA transcript driven by the Moloney LTR promoter and would subsequently be exported to the cytoplasm for translation of the selectable marker. This fusion Neo R -U5 EGS (560) could bind to the incoming viral RNA and inhibit reverse transcription and proviral integration. In this instance, inhibition would not be mediated by RNase P cleavage, as the enzyme component of the RNase P complex is localized in the nucleolus and nucleoplasm of the nucleus. [25] [26] [27] Rather the inhibition would be attributed to antisense activity and RNase degradation of RNA hybrids. However, this mechanism is unlikely as similar inhibition of viral infection would have been expected with the disabled U5 EGS (560D), which shared the same EGS as the active form but no site for binding the RNase P enzyme. Thus, it is unlikely that the inhibition of viral replication is due to the antisense effect of the U5 EGS fused to the Neo R transcript. Inhibition of incoming virus may still be a viable possibility when the pre-integration complex (PIC) of the lentivirus enters the nucleus of the infected cell, where both the RNase P enzyme and the second form of the active U5 EGS (560) transcript coexist. 28, 29 Replication of HIV-1 in non-dividing and slowly proliferating cell populations is dependent upon the active import of the viral PIC into the nucleus. 30 Formation of the PIC is required for reverse transcription of viral genomic RNA to proviral DNA. When the PIC initially arrives at the perinuclear region and the nucleus, the viral genomic RNA is present along with incomplete proviral DNA molecules. At this point, the viral RNA is susceptible to EGS binding and RNase P cleavage. Expression of the second U5 EGS (560) is driven by the tRNA promoter and produces a single U5 EGS (560) molecule. This molecule should remain localized in the nuclear region of cells expressing the EGS where the protein component of RNase P is in abundance. When the PIC including the HIV genomic RNA is localized in this region, it is possible that the U5 EGS (560) could hybridize with its target sequence followed by cleavage by the RNase P enzyme. Such a mechanism would prevent production of proviral DNA and subsequent integration into the host cell genome thereby interrupting the viral cycle and preventing infection. This mechanism could account for the results obtained using real-time PCR to detect HIV-1 proviral DNA in cellular genomic DNA isolated from experimental and control cells exposed to HIV-1. HIV-1 proviral DNA was readily amplified and detected in genomic DNA from untreated M4C8 and cells expressing the inactive U5 EGS (560D) infected with HIV-1 MN throughout the investigation. However, no proviral DNA could be detected in M4C8 cells expressing the active U5 EGS (560) over the same time periods, suggesting reverse transcription of viral RNA was not completed and integration was not achieved. These observations, along with the other measures of viral infection and production in cells treated with active U5 EGS (560) and antisense control molecules, lend support to this scenario of RNase P-mediated inhibition of viral RNA as the PIC arrives at the nucleus. This stage of viral infection would serve as the most effective time for an active EGS to mediate RNase P inhibition, as the number of viral RNA targets to be eliminated and prevent infection is limited to incoming viral RNA genomes.
One final scenario could suggest that proviral integration is achieved in cells expressing the active U5 EGS (560), but is not detected using PCR and cellular DNA samples. This would imply that RNase P-mediated inhibition would have to occur at the level of viral genome transcription. This scenario is attractive, as all of the components for recognition, hybridization and subsequent cleavage of target mRNA would be localized in the nuclear region of infected cells. Transcription of early genes, such as nef, tat and rev, would not be completed thereby preventing the down-regulation of CD4 from the surface of cells treated with the active U5 EGS (560). Furthermore, RNase P-mediated inhibition of viral transcription would preclude translation of structural proteins, preventing detection of the p24 gag antigen and expression of HIV gp160 involved in the formation of cell syncytia. Finally, inhibition of viral replication at this stage of the viral cycle would prevent expression of viral gene products that promote apoptosis of infected cells. These last two scenarios would explain the observations and data obtained from CD4 + T cells expressing the active U5 EGS (560) and lack thereof for cells expressing the inactive U5 RNase P EGS. However, the inability to detect HIV-1 proviral DNA in cells expressing the active U5 EGS (560) lends support to the inhibition of incoming viral RNA in the PIC rather than post-reverse transcription and integration. Further investigation involving PCR techniques for proviral DNA and mRNA transcripts, as well as immunohistochemistry for viral protein production may provide insight into the precise point where U5 EGS (560) interrupts the HIV-1 cycle of infection.
The use of targeted RNase P EGS molecules as specific therapeutic and research tools is a new approach to gene interference strategies for infectious diseases and human malignancies. Carefully designed RNase P EGS molecules offer the advantages attributed to antisense and ribozyme technologies without the disadvantages of inappropriate cleavage or the requirement for specific sequences within the target mRNA. As a potential therapy for HIV infection, these RNase P molecules could be used to treat non-infected, autologous stem cell grafts, thereby protecting these altered cells from infection following transplantation to reconstitute the immune system of HIV patients. 31 Future directions could include the production of synthetic RNase P EGS molecules that could be administered much like pharmaceuticals or in combination with targeted drug delivery systems, 32 as an effective intervention for HIV infection.
Materials and methods
Cell culture and viral stocks
The MOLT-4 clone 8 (M4C8) cell line is a CD4 + T cell line permissive to both HIV-1 and HIV-2.
33 M4C8 were the kind gift of M Hayami (Institute for Virus Research, Kyoto University, Kyoto, Japan). HIV-1 MN was produced in our laboratory using a constitutively expressing T cell line and titered at 10 4 TCID 50 . HIV-2 KR used for RNase P EGS specificity and permissive control experiments was also produced in our laboratory using M4C8 cells.
RNase P EGS design and vector construction
The Moloney murine leukemia virus (MoMLV) vectors pLNL-6-560 and pLNL-6-560D were engineered by inserting a t-RNA val promoter RNase P cassette into the unique NheI site located in the U3 region of the MoMLV 3'LTR. The 560 RNase P molecule was created by annealing of the upper-strand primer 560US (5'CGGGAT CCACATCAAGGTTCGTGCCCTTCCAGACGGGCAAC CATACGCGTCG 3') and lower-strand primer 560LS (5'C GACGCGTATGGTTGCCCGTCTGGAAGGGCACGAA 3'). The annealed product was subject to PCR amplification (94°, 48°and 72°C for 10 s at each temperature). The frag-ment was digested by BamHI and MluI and ligated into the modified pLNL-6 t-RNA containing vector. The same procedure was used to construct the pLNL-6-560D vector using the following upper-strand primer 560D US (5'AG GATCCGGCCAAACATCCCAGACGGGCACGCGTCG 3') and lower-strand primer 560DLS (5'CGACGCGTGCCCG TCTGGGATGTTTGGCCGGATCCT 3'). The integrity of the new constructs were confirmed by DNA sequencing.
Transfection and selection of M4C8 cells M4C8 cells were seeded at 10 5 cells per ml of media into uncoated T25 suspension flasks. Cells were transfected with the U5 EGS (560) or (560D) control plasmid (2 g) using Fugene (Roche Biochemicals, Indianapolis, IN, USA) according to the manufacturer's specifications. Transfected cells were selected for neomycin resistance by culturing cells in the presence of G418 (500 g/ml of media). Selected cells were maintained in RPMI supplemented with 10% FCS, 1% penicillin-streptomycin solution and G418. Seven days before infection with HIV-1 or HIV-2, the selection medium was removed from the transfected cells and replaced with normal culture medium without G418.
Cell proliferation assays
Colorimetric assays for the non-radioactive quantification of cellular proliferation, viability and cytotoxicity were completed on selected M4C8 cells (10 4 /well) in the presence and absence of G418 to ensure all cells used for this investigation had similar proliferation rates. The Cell Proliferation Kit I (Roche Biochemicals) was used according to the manufacturer's specifications. Levels of the formazan dye generated by cells in this assay were measured (570-630 nm) using a scanning multiwell spectrophotometer (PerkinElmer Wallac, Gaithersburg, MD, USA) and directly correlate to the proliferation of viable cells.
Confirmation of vector expression using real-time RT-PCR
Total RNA was isolated from M4C8, M4C8 + U5 EGS 560 and M4C8 + U5 EGS 560D cells using a High Pure RNA Isolation kit (Roche Diagnostics). 300 ng of each RNA sample, as well as serial dilutions of in vitro transcribed GAPDH RNA were analyzed using real-time RT-PCR and the LightCycler. Following the instructions of the RNA amplification SYBR Green kit (Roche Diagnostics) and adding the 5GAP (5'GAAGGTGAAGGTCGGAGTC 3') and 3GAP (5'GAAGATGGTGATGGGATTTC 3') primers with 300 ng of total RNA, real-time PCR was performed (one cycle at 52°C, for 10 min; 30 cycles at 95°C 1 s, 60°C 5 s, 72°C for 10 s). This reaction provided a quantitative measurement of RNA isolated from each cell sample to compare with spectrophotometric quantitation. Levels of GAPDH for each sample as a measure of RNA isolation were similar for each transfected and control cell sample (data not shown).
cDNA was generated using 300 ng of each RNA sample with random hexamers according to the manufacturer's specifications using the Gene Amp RNA PCR Core Kit (Applied Biosystems, Foster City, CA, USA). Two l of cDNA was analyzed using quantitative PCR and the LightCycler for levels of GAPDH, neomycin resistance and each RNase P EGS. Levels of GAPDH were analyzed to determine that similar levels of cDNA were generated from each RNA sample using 5GAP and Gene Therapy 3GAP primers with the DNA amplification SYBR Green kit (Roche Diagnostics) and real-time PCR was carried out (30 cycles at 95°C 1 s, 60°C 5 s, 72°C for 10 s). Melting point analysis using the LightCycler confirmed the generation of a single product corresponding to the GAPDH fragment.
To confirm selected cell populations were transfected with each retroviral expression plasmid, real-time PCR analysis was completed using primers specific for the neomycin resistance (Neo R ) selectable marker and Neo R plasmid DNA standards. Again 2 l of cDNA was analyzed with the DNA amplification SYBR Green kit using the 5neo (5' GATCAAGAGACAG GATGAGG 3') and 3neo (5' CAGCCATGATGGATACTTTC 3') primers. The real-time PCR conditions were one cycle at 95°C for 30 s, followed by 30 cycles at 95°C 1 s, 60°C 5 s, 72°C for 20 s. Melting point analysis using the LightCycler confirmed the generation of a single product corresponding to the Neo R fragment (melting point = 93.49°C). In addition, DNA isolated from transfected and nontransfected cell populations were analyzed for the presence of the Neo R gene to provide insight into the number of plasmid copies per cell. DNA samples from 100 000 cells were initially analyzed using real-time PCR and primers specific for the B-7 gene to ensure equal amounts of DNA were used for each reaction. Using real-time PCR and serial dilutions of a Neo R containing plasmid (2.6 × 10 5 to 2.6 × 10 9 copies), DNA samples were analyzed for the presence of the Neo R gene using PCR conditions described above. The average number of plasmid copies per cell was calculated based upon DNA extraction, cell number and quantitative PCR. The average amount of DNA extracted from 100 000 M4C8 cells (total extractions = 10) was calculated to be 0.6 pg/cell. Since the amount of DNA for each PCR reaction was known, we could approximate the number of cells per PCR reaction and subsequently calculate the number of plasmid copies per cell based upon the quantitative PCR results and the plasmid standards. The number of copies of retroviral plasmid per cell was calculated to be approximately 6.85 copies per cell for M4C8 + U5 EGS 560 and 11.85 copies per cell for M4C8 + U5 EGS 560D.
Finally, levels of expression for each RNase P EGS (U5 EGS 560 and 560D) was measured using real-time PCR analysis with control plasmid DNA. Again 2 l of cDNA was analyzed with the DNA amplification SYBR Green kit using the LNL6-2876 (5'AGGTCACTGCGTGGATGG 3') and either MN560LS or primers corresponding to each EGS. The real-time PCR conditions were one cycle at 95°C for 30 s, followed by 30 cycles at 95°C 2 s, 51°C 5 s, 72°C for 45 s. Melting point analysis using the LightCycler confirmed the generation of a single product corresponding to each U5 EGS fragment (U5 EGS 560 = 93.0°C and U5 EGS 560D = 93.5°C).
Infection of M4C8 with HIV-1 MN and HIV-2 KR
Experimental (expressing the active or disabled U5 EGS) and control M4C8 cells (10 5 cells in 500 l of media) were placed in 1.5 ml microcentrifuge tubes. HIV-1 MN (MOI = 0.01) was added to each tube and incubated with the cells for 6 h. Following incubation, cells were washed five times with culture media via centrifugation to remove remaining virus. Cells were resuspended in 7 ml of fresh culture media and primary (time = zero) cell and supernatant samples were harvested for analysis. Supernatants and cell samples were harvested from each culture every 7 days for analysis for HIV infection, induction of apoptosis and levels of CD4 expression. In order to assess specificity of the RNase P EGS, duplicate cell samples were infected with HIV-2 KR (MOI = 0.01) and processed using an identical protocol.
Detection of HIV-1 proviral DNA using real-time PCR Genomic DNA was isolated from cell samples harvested every 7 days after infection using a commercial kit (Perfect Blood gDNA Mini, Eppendorf Scientific, Westbury, NY, USA). DNA was quantitated using spectrophotometry and analyzed for the presence of HIV-1 proviral DNA as an indication of infection using realtime PCR and the LightCycler. PCR mixtures were prepared according to the DNA Amplification SYBR Green I Kit (Roche Biochemicals) using the SK38 (5' ATAATCCACCTATCCCAGTAGGAGAAAT 3') and SK39 (5' TTTGGTCCTTGTCTTATGTCCAGAATGC 3') oligonucleotides specific for the viral sequence encoding a region of HIV-1 gag protein. The LightCycler was utilized for PCR amplification and detection of HIV-1 proviral DNA as a measure of viral infection of experimental and untreated CD4 + T cells over time. The real-time PCR conditions were 30 cycles at 95°C for 1 s, 60°C for 5 s, 72°C for 20 s. Melting curve profiles were completed for each amplified product over a temperature range of 65 to 88°C.
P24/P26 antigen capture assays
HIV-1 MN replication and production was monitored by determination of the p24 gag antigen concentration (Coulter p24 Antigen Assay, Beckman-Coulter, Miami, FL, USA) in the culture supernatants harvested at various time-points. Productive HIV-2 KR infection was monitored by determination of the p26 gag antigen concentration (Coulter p26 SIV Antigen Assay) in the culture supernatants.
CD4 and Annexin V detection using flow cytometry
Non-infected and infected cell samples were evaluated in triplicate for CD4 expression and levels of phosphatidylserine as a measure of apoptosis using flow cytometry. Cells were fixed with 10% buffered formalin before staining and analysis. Anti-human CD4 monoclonal antibody (OKT4; Beckman-Coulter) labeled with phycoerythrin (PE) was used to detect CD4 expression by non-infected and HIV infected M4C8 cells and controls. An appropriate nonspecific murine immunoglobulin control (Mouse IgG 2b ; Myelin BP, BD Biosciences, San Diego, CA, USA) was included with each M4C8 cell sample to monitor nonspecific staining via the Fc receptor of normal lymphocytes. Nonspecific binding values were less than 2% for all samples analyzed. An apoptosis detection kit (Beckman-Coulter) utilizing FITC-labeled Annexin V, a calcium and phospholipid-specific protein, to bind to phosphatidyl serine was used to detect apoptosis following infection with HIV.
